Addressing Challenging Cases in the Management of DMD Therapy for MS
A CME-certified program held in conjunction with the North Carolina Neurological Society (NCNS)



Registration Statement


By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements below.


Registration

  VenueCityStateDate
View Agenda  The Grandover HotelGreensboro,NC Saturday
Feb 20, 2016 4:45 PM


This program is part of a series of Topics in Neurology programs; Click Here for information.


Program Description


The National Multiple Sclerosis Disease Management Consensus Statement recommends continuous use of disease modifying drug (DMD) therapy, initiating a DMD as soon after definitive diagnosis as possible, and consideration of DMD therapy in select high-risk patients with a first attack. The push for earlier diagnosis and earlier initiation of DMD therapy makes MS management ever more complicated. Analysis of MS treatment trends shows that there is considerable room for improvement in the management of DMD therapy in MS. The emergence of new DMD therapies with different mechanisms of action and efficacy and safety profiles contributes to complexity for the clinician, as do the continuing scientific advances in MRI parameters and biomarker research. The availability of many different DMDs has also made ongoing management, patient counseling, and long-term DMD decision-making progressively difficult. 

Addressing Challenging Cases in the Management of DMD Therapy for MS will provide neurologists and other MS clinicians with the latest research and clinical management information on DMD therapies, diagnostic MRI measures, and biomarkers in order to improve the overall management of their patients with MS.

Target Audience

This activity is intended for neurologists, MS specialists, primary care physicians, and other health care professionals who manage patients with multiple sclerosis (MS).  


Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Apply newer MRI criteria and other prognostic measures to improve diagnosis and initiate DMD therapy earlier in the course of MS 
  • Evaluate the mechanisms of action and efficacy and safety profiles of current and emerging DMD therapies to develop individualized MS therapies that optimize adherence and improve patient outcomes 
  • Integrate evidence from recent diagnostic and prognostic biomarker studies to improve monitoring of disease activity and response to DMD therapy in MS

Speaking Faculty


Mark B. Skeen, MD
Associate Professor and Head
Department of Neurology
Division of Multiple Sclerosis and Neuroimmunology
Duke University Medical Center
Durham, NC


Steering Committee


Suhayl Dhib-Jalbut, MD
Professor and Chairman
Department of Neurology
Rutgers -New Jersey Medical School and -Robert Wood Johnson Medical School
Chief, Neurology Service
Robert Wood Johnson University Hospital
New Brunswick, NJ

Aaron E. Miller, MD
Professor of Neurology, Icahn School of Medicine at Mount Sinai
Medical Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, NY


Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Designation Statement


The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email contact@potomacme.org.


Disclosure Information


Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. 

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. 

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias. 

FDA Disclosure

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses. 


Method of Participation


To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be provided upon submission of a completed evaluation form. 

There is no fee associated with this program.


Special Services


Event staff will be glad to assist you with any special needs. Please email specialservices@rockpointe-pcme.com at least 5 days prior to the program.  


Provided by


Jointly provided by Potomac Center for Medical Education and Rockpointe


      

 

Supported by

This educational activity has been supported through an independent educational grant from Teva Pharmaceuticals



Registration

  VenueCityStateDate
View Agenda  The Grandover HotelGreensboro,NC Saturday
Feb 20, 2016 4:45 PM